Business Description
NGM Biopharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US62921N1054
Description
NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include, NGM313 (MK-3655), NGM120, NGM621, and NGM395 among others. These are focused on NASH, diabetes, oncology, AMD and metabolic disease.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 104.41 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.98 | |||||
| Beneish M-Score | -6.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -65.2 | |||||
| 3-Year EBITDA Growth Rate | -8.4 | |||||
| 3-Year EPS without NRI Growth Rate | -4.9 | |||||
| 3-Year FCF Growth Rate | -9.1 | |||||
| 3-Year Book Growth Rate | -23.3 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.43 | |||||
| 9-Day RSI | 43.66 | |||||
| 14-Day RSI | 48.54 | |||||
| 6-1 Month Momentum % | 19.53 | |||||
| 12-1 Month Momentum % | -60.05 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.79 | |||||
| Quick Ratio | 7.79 | |||||
| Cash Ratio | 7.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.5 | |||||
| Shareholder Yield % | 3.57 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -3429.09 | |||||
| Net Margin % | -3223.34 | |||||
| FCF Margin % | -3021.37 | |||||
| ROE % | -71.83 | |||||
| ROA % | -62.02 | |||||
| ROIC % | -605.18 | |||||
| ROC (Joel Greenblatt) % | -1728.12 | |||||
| ROCE % | -76.4 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 29.06 | |||||
| PB Ratio | 0.86 | |||||
| Price-to-Tangible-Book | 0.86 | |||||
| EV-to-EBIT | 0.24 | |||||
| EV-to-EBITDA | 0.24 | |||||
| EV-to-Revenue | -8.18 | |||||
| EV-to-FCF | 0.27 | |||||
| Price-to-Net-Current-Asset-Value | 0.94 | |||||
| Price-to-Net-Cash | 1.03 | |||||
| Earnings Yield (Greenblatt) % | 416.67 | |||||
| FCF Yield % | -103.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:NGM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
NGM Biopharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 4.417 | ||
| EPS (TTM) ($) | -1.73 | ||
| Beta | 0.57 | ||
| Volatility % | 107.11 | ||
| 14-Day RSI | 48.54 | ||
| 14-Day ATR ($) | 0.048691 | ||
| 20-Day SMA ($) | 1.555 | ||
| 12-1 Month Momentum % | -60.05 | ||
| 52-Week Range ($) | 0.6002 - 4.69 | ||
| Shares Outstanding (Mil) | 83.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
NGM Biopharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
NGM Biopharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
NGM Biopharmaceuticals Inc Frequently Asked Questions
What is NGM Biopharmaceuticals Inc(NGM)'s stock price today?
The current price of NGM is $1.54. The 52 week high of NGM is $4.69 and 52 week low is $0.60.
When is next earnings date of NGM Biopharmaceuticals Inc(NGM)?
The next earnings date of NGM Biopharmaceuticals Inc(NGM) is 2024-05-03 Est..
Does NGM Biopharmaceuticals Inc(NGM) pay dividends? If so, how much?
NGM Biopharmaceuticals Inc(NGM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers